Can a 13-year-old child safely take Lariam (mefloquine) for malaria prophylaxis or treatment?

Can a 13-Year-Old Use Lariam (Mefloquine)?

Yes, a 13-year-old can safely use Lariam (mefloquine) for malaria prophylaxis or treatment, provided the child weighs more than 15 kg (approximately 30 lbs) and has no contraindications such as a history of seizures, psychiatric disorders, or cardiac conduction abnormalities. 1

Weight-Based Eligibility

• Mefloquine is contraindicated in children weighing less than 15 kg (30 lbs) according to CDC guidelines, though more recent pharmacokinetic data suggest possible use in smaller children under specialized circumstances. 1, 2
• A typical 13-year-old will weigh well above this threshold, making mefloquine an appropriate option. 1
• The drug has been studied and used safely in children of all ages who meet the weight requirement, with data available for more than 6,000 children across all weight categories. 3

Dosing for Adolescents

For Prophylaxis:

• Administer 5 mg base/kg (approximately 250 mg for most adolescents) once weekly, starting one week before travel and continuing for four weeks after return from the malaria-endemic area. 4, 5
• The one-week pre-travel initiation allows establishment of a dosing routine and early detection of adverse effects while still at home with access to medical care. 2, 6

For Treatment:

• Give 15 mg base/kg as an initial dose, followed by 10 mg/kg 8-24 hours later for uncomplicated malaria. 4
• This split-dose regimen reduces vomiting, which can be problematic at higher single doses. 3

Absolute Contraindications to Screen For

Before prescribing mefloquine to any adolescent, you must exclude:

• History of seizures or epilepsy – mefloquine can precipitate convulsions. 1, 2
• Psychiatric disorders including depression, anxiety, or psychosis – mefloquine causes neuropsychiatric adverse effects in a dose-dependent manner. 1, 2
• Known hypersensitivity to mefloquine. 1, 2
• Concurrent use of β-blockers or drugs that alter cardiac conduction – risk of cardiac toxicity. 1, 2
• Severe liver impairment – mefloquine is hepatically metabolized. 2
• Pregnancy or inadequate contraception in females of childbearing age – though less relevant for a 13-year-old, this should be considered in post-menarchal girls. 1, 2

Expected Adverse Effects

Neuropsychiatric Effects:

• Approximately 70% of neuropsychiatric side effects occur within the first three weekly doses, which is why starting one week before departure is critical. 2, 6
• Common effects include abnormal dreams (reported in 12-31% depending on comparison), insomnia (12-13%), anxiety (6-18%), and depressed mood (6-11%) when compared to alternative antimalarials. 7
• Serious neuropsychiatric reactions (hallucinations, psychosis) occur rarely at prophylactic doses (approximately 0.01% of users) but are more frequent with treatment doses. 1, 2, 6

Gastrointestinal Effects:

• Minor side effects such as nausea, diarrhea, and anorexia occur in approximately 10% of pediatric patients taking mefloquine. 8
• These effects are generally transient and self-limited. 1

Discontinuation Rates:

• In pediatric studies, only 2 of 115 children (1.7%) stopped mefloquine due to adverse effects, demonstrating good overall tolerability in this age group. 8
• When compared to atovaquone-proguanil in adults, mefloquine users discontinue at approximately 6% versus 2%, though pediatric-specific discontinuation data show better tolerance. 7, 8

Clinical Advantages in Adolescents

• Once-weekly dosing improves compliance compared to daily regimens, particularly important in adolescents who may be less adherent. 9, 7
• Mefloquine is the drug of choice for highly chloroquine-resistant areas such as sub-Saharan Africa. 2, 6, 9
• Treatment data demonstrate good tolerability in children, with higher clearance rates in older children (5-12 years) compared to younger children, suggesting efficient metabolism in adolescents. 3

Critical Monitoring and Counseling Points

• Discontinue mefloquine immediately if psychiatric or neurologic symptoms develop and substitute an alternative antimalarial agent. 10
• Warn families that approximately 10-23% of children may experience side effects, but these rarely necessitate stopping the medication. 8
• Emphasize that the four-week post-travel continuation is essential to prevent late-emerging hepatic-stage parasites. 2, 6
• Store in child-proof containers as overdose can be fatal. 6

Alternative Agents When Mefloquine is Contraindicated

• Atovaquone-proguanil (Malarone) is preferred if mefloquine is unsuitable, with fewer neuropsychiatric effects but requires daily dosing. 2, 6, 5
• Doxycycline can be used in children ≥8 years old but causes photosensitivity and requires daily dosing. 1, 2
• Chloroquine is appropriate only for chloroquine-sensitive regions (Central America, Caribbean, Middle East) and provides inadequate protection in resistant areas. 2, 6

Common Pitfalls to Avoid

• Failing to screen for psychiatric history – this is the most important contraindication and is often overlooked. 1, 2
• Premature discontinuation after return – stopping before the four-week post-travel period eliminates protection against hepatic parasites. 2, 6
• Using mefloquine in chloroquine-sensitive areas – chloroquine is safer and equally effective in non-resistant regions. 2, 6
• Not counseling about neuropsychiatric effects – families must know to discontinue immediately if symptoms develop. 10